H.R. 10164, Supply-Chain Transparency & Regulatory Coordination. Quorum's AI analysis reads it as a net benefit — and names who gains.
H.R. 10164 · Net good
What it does
This bill directs the Secretary of Commerce to designate a senior official to lead a coordinated federal effort promoting U.S. biomanufacturing competitiveness. The official will identify supply-chain vulnerabilities, regulatory barriers, and foreign-adversary dependencies in critical biomanufacturing inputs; map federal commercialization processes; consolidate public resources; and report biennially to Congress. The bill creates no new funding, mandates, or restrictions on private industry—it is a transparency and coordination mechanism designed to reduce regulatory friction and strengthen domestic production capacity in biotechnology manufacturing.
The analysis names domestic biomanufacturing companies and suppliers — and 3 more groups — among the beneficiaries.
The trade-off
The bill's focus on 'foreign adversary' dependencies may indirectly prioritize reshoring of biomanufacturing to the U.S., potentially raising costs for companies currently reliant on lower-cost foreign suppliers—a benefit to domestic producers but a cost to consumers if passed through.
Transparency scores 85%, with a medium warning level and no provisions unrelated to the bill's subject.
Who is behind it
Filed by Robert Latta. Cosponsored by Debbie Dingell.
The week in bills
One email, Sunday: what Congress passed, what it changed, and who paid.
One link arrives to confirm the address. It is used for this email and nothing else, and every issue carries an unsubscribe link.